Back

South Korean biotech out-licensing tops ₩21 trillion as stocks fall 23.07%

Verifying
  • South Korean pharma and biotech companies signed 13 out-licensing deals this year.
  • ₩21.6637 trillion was the combined value of 11 disclosed contracts.
  • The KRX Healthcare Index fell 23.07% from the year's start.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.